Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Alzheimer's Disease

Free Subscription 15.12.2025 4 Acta Neuropathol 20 Alzheimers Dement 3 Am J Geriatr Psychiatry 1 Ann Neurol 2 BMC Geriatr 1 Brain Res 1 Dement Geriatr Cogn Disord 2 Exp Neurol 23 J Alzheimers Dis 1 JAMA 1 Lancet Neurol 3 Neurobiol Aging 3 Neurology 1 Neurosci Lett 2 Neuroscience 4 PLoS One 1 Proc Natl Acad Sci U S A 1 Science

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Acta Neuropathol

1. LIANG H, Hunt JB Jr, Ma C, Kovalenko A, et al
   Probing tau citrullination in Alzheimer's disease brains and mouse models of tauopathy.
   Acta Neuropathol. 2025;150:61.
   PubMed         Abstract available
   
   
2. LE LTHL, Lee G, Shin JW, Shim YM, et al
   Phospho-tau Ser356 is mostly confined to pre-NFT neurons in Alzheimer's pathology.
   Acta Neuropathol. 2025;150:62.
   PubMed        
   
   
3. TAYLOR LW, Simzer EM, Young LFP, Holt K, et al
   Confirmation of p-tau Ser356's association with Alzheimer's disease pathology and lowering in response to WZ4003 treatment in brain slice cultures. Reply to: "Phospho-tau Ser356 is mostly confined to pre-NFT neurons in Alzheimer's pathology".
   Acta Neuropathol. 2025;150:63.
   PubMed        
   
   
4. MOHANTY R, Wheatley S, Chiotis K, Marseglia A, et al
   Distinct cerebrovascular pathways underlying Alzheimer's disease-related neurodegeneration.
   Acta Neuropathol. 2025;150:64.
   PubMed         Abstract available
   
   

   
   Alzheimers Dement

5. SACHDEV P
   Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
   Alzheimers Dement. 2025 Dec 12. doi: 10.1002/alz.12924.
   PubMed        
   
   
6. KARAHAN H, Hartigan K, Al-Amin MM, John SK, et al
   Deletion of neuronal Idol ameliorates Alzheimer's disease-related pathologies via APOE receptors.
   Alzheimers Dement. 2025;21:e70949.
   PubMed         Abstract available
   
   
7. BRODMAN ST, Heaton N, Triana-Baltzer G, Zeng X, et al
   Plasma biomarkers, brain amyloid-beta pathology, and cortical thickness in a non-Hispanic White and Black/African American middle-aged community cohort: The HCP-CoBRA study.
   Alzheimers Dement. 2025;21:e70985.
   PubMed         Abstract available
   
   
8. PYUN JM, Park YH, Kim S, Nho K, et al
   Polygenic risk score predicts pathologically confirmed cerebral amyloid angiopathy.
   Alzheimers Dement. 2025;21:e70958.
   PubMed         Abstract available
   
   
9. PAN FF, Huang L, Wang Y, Huang Q, et al
   Plasma P-tau217, GFAP, and NfL as biomarkers for Alzheimer's disease: role in disease stratification, pathological progression, and cognitive decline.
   Alzheimers Dement. 2025;21:e70987.
   PubMed         Abstract available
   
   
10. KEMNA RE, Kueck PJ, Blankenship A, John CS, et al
    Acute effects of lactate infusion on metabolism, AD biomarkers, and cognition: The LEAN study.
    Alzheimers Dement. 2025;21:e70984.
    PubMed         Abstract available
    
    
11. CARY GA, Li Q, Wiley JC, Paisie CA, et al
    Integrated phenotypic and proteomic screening identifies top-tier Alzheimer's disease therapeutic targets.
    Alzheimers Dement. 2025;21:e71008.
    PubMed         Abstract available
    
    
12. PORTA-MAS C, Grau-Rivera O, Gispert JD, Blasco GS, et al
    Validation status of cognitive digital assessments by the FDA BEST framework and context of use in preclinical AD studies: A systematic review.
    Alzheimers Dement. 2025;21:e70753.
    PubMed         Abstract available
    
    
13. LIN Z, Hong Y, Hu Y, Xiao Q, et al
    White matter hyperintensity modulates the amyloid-tau-cognition association and anti-amyloid treatment efficacy in asymptomatic older adults.
    Alzheimers Dement. 2025;21:e70990.
    PubMed         Abstract available
    
    
14. MONSERRATT LH, Morales JA, Mohammed A, Ovalle-Eliseo S, et al
    Validity of gold-standard clinical outcome assessments in U.S. Latinx-Hispanic participants enrolled in Alzheimer's disease clinical trials: A literature review.
    Alzheimers Dement. 2025;21:e70918.
    PubMed         Abstract available
    
    
15. 
    Correction to "Putaminal hypermetabolism identifies Lewy body co-pathology in Alzheimer's disease".
    Alzheimers Dement. 2025;21:e71013.
    PubMed        
    
    
16. YE BS, Park SH, Jeon S, Kang S, et al
    Degenerative pathologies on cortical biopsy, dopaminergic depletion, and shunt efficacy in iNPH.
    Alzheimers Dement. 2025;21:e70974.
    PubMed         Abstract available
    
    
17. MORETTI DV, Kuhn E, Dubbelmann MA, Sikkes SAM, et al
    Clinical definition, biological characterization, and detection guidelines of subjective cognitive decline due to Alzheimer's disease and related dementia: A position paper from ISTAART SCD PIA.
    Alzheimers Dement. 2025;21:e70847.
    PubMed         Abstract available
    
    
18. HE D, Langhough RE, Van Hulle C, Basche K, et al
    Development of language composites for enhanced sensitivity to multiple plasma biomarkers.
    Alzheimers Dement. 2025;21:e70975.
    PubMed         Abstract available
    
    
19. VAN DYCK CH, Sperling R, Johnson K, Dhadda S, et al
    Long-term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the clarity AD open-label extension study.
    Alzheimers Dement. 2025;21:e70905.
    PubMed         Abstract available
    
    
20. MORENO N, Shchankin N, Fung L, Puangmalai N, et al
    APOE isoform-associated tau oligomer polymorphs differ in synaptotoxicity and seeding activity.
    Alzheimers Dement. 2025;21:e70965.
    PubMed         Abstract available
    
    
21. CASTELLANO T, Wang TC, Nolan E, Wu Y, et al
    APOE, ABCA7, and RASGEF1C are associated with earlier onset of amyloid deposition from more than 4000 harmonized positron emission tomography images.
    Alzheimers Dement. 2025;21:e71006.
    PubMed         Abstract available
    
    
22. ROZENBLUM G, Ait-Aissa K, Zahran G, Alipour M, et al
    Unraveling the oral microbiome's role in Alzheimer's disease: From pathophysiology to therapeutic potential.
    Alzheimers Dement. 2025;21:e71011.
    PubMed         Abstract available
    
    
23. MUNDADA NS, Lyu X, Brown CA, Sadeghpour N, et al
    Enrichment of patients with concomitant limbic-predominant age-related TDP-43 encephalopathy (LATE) on the Alzheimer's disease continuum using hippocampal volume.
    Alzheimers Dement. 2025;21:e70970.
    PubMed         Abstract available
    
    
24. 
    Correction to "ACLY regulates autolysosome acidification through tubulin acetylation-mediated assembly of V-ATPase subunits in Alzheimer's disease model mice".
    Alzheimers Dement. 2025;21:e71018.
    PubMed        
    
    

    
    Am J Geriatr Psychiatry

25. ROSENBERG PB, Amjad H, Burhanullah H, Nowrangi M, et al
    A Randomized Controlled Trial of the Safety and Efficacy of Dronabinol for Agitation in Alzheimer's Disease.
    Am J Geriatr Psychiatry. 2025 Nov 10:S1064-7481(25)00506.
    PubMed         Abstract available
    
    
26. TAMPI RR
    Dronabinol for Agitation in Alzheimer's Disease.
    Am J Geriatr Psychiatry. 2025 Nov 17:S1064-7481(25)00526.
    PubMed        
    
    
27. FENELON A, Chen J
    Housing Assistance and Health Care Access Among Older Adults with Alzheimer's Disease and Related Dementias: Evidence from Multisource Linked Survey-Administrative Data.
    Am J Geriatr Psychiatry. 2025 Nov 9:S1064-7481(25)00527.
    PubMed         Abstract available
    
    

    
    Ann Neurol

28. GRAFF-RADFORD J, Syrjanen JA, Vemuri P, Lowe VJ, et al
    Predictive Value of Plasma Biomarkers in Tau-PET Transitions.
    Ann Neurol. 2025 Sep 10. doi: 10.1002/ana.78003.
    PubMed         Abstract available
    
    

    
    BMC Geriatr

29. DENG H, Lee TA, Gaber CE, Kim K, et al
    Treatment patterns of symptomatic treatments for Alzheimer's disease and related dementias.
    BMC Geriatr. 2025 Dec 6. doi: 10.1186/s12877-025-06745.
    PubMed        
    
    
30. GUO H, Guo T, Wang X, Bao Y, et al
    LAX1 as a core biomarker in Alzheimer's disease and periodontitis via the STAT signaling pathway.
    BMC Geriatr. 2025 Dec 12. doi: 10.1186/s12877-025-06865.
    PubMed         Abstract available
    
    

    
    Brain Res

31. MAJUMDER M, Dutta D, Paidi RK, Pahan K, et al
    Activation of PPARalpha by gemfibrozil lowers tau-associated neuropathology in the MAPT mouse model of Alzheimer's disease.
    Brain Res. 2025 Dec 7:150089. doi: 10.1016/j.brainres.2025.150089.
    PubMed         Abstract available
    
    

    
    Dement Geriatr Cogn Disord

32. ENGEDAL K, Wahlund LO, Musaeus CS, Hoegh P, et al
    The Ability of Electroencephalography Using Statistical Pattern Recognition to Predict Conversion from Subtypes of Mild Cognitive Impairment to Dementia: A 5-Year Follow-Up Study.
    Dement Geriatr Cogn Disord. 2025;54:362-373.
    PubMed         Abstract available
    
    

    
    Exp Neurol

33. PAN JZ, Yu MY, Tian MZ, Liu R, et al
    Calcaratarin D exerts neuroprotective effects in Alzheimer's disease mouse model by inhibiting CERT-mediated NF-kappaB pathway.
    Exp Neurol. 2025;397:115585.
    PubMed         Abstract available
    
    
34. SUPASAI S, Suntaratti P, Odton M, Longji T, et al
    HMGB1 Box A gene therapy reverses cognitive and neuropathological features in AlCl(3)/D-galactose rat model of Alzheimer's disease.
    Exp Neurol. 2025 Dec 8:115583. doi: 10.1016/j.expneurol.2025.115583.
    PubMed         Abstract available
    
    

    
    J Alzheimers Dis

35. TSENG P
    Does weak gamma entrainment still work? Rethinking the comfort-efficacy trade-off in 40 Hz sensory stimulation.
    J Alzheimers Dis. 2025;108:1517-1519.
    PubMed         Abstract available
    
    
36. TIKKANEN V, Paajanen TI, Heikkinen AL, Solje E, et al
    Combining a computerized cognitive test with serum biomarkers improves detection of early-onset neurodegenerative disorders.
    J Alzheimers Dis. 2025;108:1647-1658.
    PubMed         Abstract available
    
    
37. SHI Y, Ma H, Li H, Wang Y, et al
    Sennoside A alleviating cognitive impairment in APP/PS1 mice via balancing microbiome metabolism.
    J Alzheimers Dis. 2025;108:1659-1676.
    PubMed         Abstract available
    
    
38. HELLQUIST E, Janelidze S, Weidung B, Franzon K, et al
    Plasma p-tau(217) correlates strongly with cerebrospinal fluid Abeta(42) and increases over a ten-year period in amyloid-positive, non-demented very old men.
    J Alzheimers Dis. 2025;108:1778-1789.
    PubMed         Abstract available
    
    
39. AZEVEDO CV, Otaviano SFSD, Campos HC, Figueiredo EV, et al
    Distinct effects of long-term resistance exercise on cognitive deficits, neurotrophins, and amyloid pathology in male and female APP/PS1 mice.
    J Alzheimers Dis. 2025;108:1790-1806.
    PubMed         Abstract available
    
    
40. WANG W, Wei X, Sun Z, Zhang X, et al
    Uncovering the toxicological impact of benzo[a]pyrene on Alzheimer's disease via network toxicology, machine learning, and single-cell transcriptomics.
    J Alzheimers Dis. 2025 Dec 12:13872877251405468. doi: 10.1177/13872877251405468.
    PubMed         Abstract available
    
    
41. TSAI A, Gunn-Sandell LB, Wyman-Chick KA, Wang Y, et al
    Sex differences for symptoms prior to dementia onset in people with Lewy body pathology compared to pure Alzheimer's disease pathology.
    J Alzheimers Dis. 2025 Dec 12:13872877251405437. doi: 10.1177/13872877251405437.
    PubMed         Abstract available
    
    
42. AKAIKE S, Ogata A, Nakagawa Y, Ura S, et al
    The Visual Image Simple Recognition Test, a language-minimized recognition test: Psychometric and clinical evaluation in Alzheimer's disease.
    J Alzheimers Dis. 2025 Dec 12:13872877251405433. doi: 10.1177/13872877251405433.
    PubMed         Abstract available
    
    
43. SOLTYS A, Wnuk M
    Types of caregivers for people with Alzheimer's disease in the context of their value system and personality traits.
    J Alzheimers Dis. 2025 Dec 12:13872877251406616. doi: 10.1177/13872877251406616.
    PubMed         Abstract available
    
    
44. BATLLE P, Darcy M, Levine M, Hamzi B, et al
    Benchmarking Gaussian processes for prediction and data assimilation of Alzheimer's disease progression.
    J Alzheimers Dis. 2025 Dec 12:13872877251404082. doi: 10.1177/13872877251404082.
    PubMed         Abstract available
    
    
45. VILLAREJO GALENDE A, Gonzalez-Sanchez M, Hilario A, Llamas-Velasco S, et al
    Severe symptomatic amyloid-related imaging abnormalities in Alzheimer's disease: Two case reports and systematic review of reported cases.
    J Alzheimers Dis. 2025 Dec 12:13872877251404505. doi: 10.1177/13872877251404505.
    PubMed         Abstract available
    
    
46. CHOI YH, Kim H, Hong S, Baek C, et al
    Deep-learning analysis of speech using mel-spectrograms for the assessment of mild cognitive impairment and Alzheimer's disease.
    J Alzheimers Dis. 2025 Dec 12:13872877251401202. doi: 10.1177/13872877251401202.
    PubMed         Abstract available
    
    
47. GUY TO, Ghanem A, Berry DS, Hernandez NC, et al
    Blood-based Alzheimer's disease biomarkers and cognitive decline in essential tremor.
    J Alzheimers Dis. 2025 Dec 12:13872877251404035. doi: 10.1177/13872877251404035.
    PubMed         Abstract available
    
    
48. NAKAMURA Y, Kurokawa T, Terashima S, Nishimura A, et al
    Efficacy and safety of a novel, extended-release rivastigmine transdermal patch (TW-4752N) in patients with Alzheimer's disease: A 24-week randomized, double-blind trial with a 28-week open-label extension.
    J Alzheimers Dis. 2025 Dec 9:13872877251401601. doi: 10.1177/13872877251401601.
    PubMed         Abstract available
    
    
49. DU E, Tian J
    Hippocampal transcriptome-wide association analysis of shared genetic risks between posttraumatic stress disorder and Alzheimer's disease.
    J Alzheimers Dis. 2025 Dec 9:13872877251400775. doi: 10.1177/13872877251400775.
    PubMed         Abstract available
    
    
50. ASIH PR, Morris CW, Wang H, Pedrini S, et al
    Plasma soluble TREM2 is associated with plasma pTau-181 and pTau-231 in cognitively normal older adults at risk of Alzheimer's disease.
    J Alzheimers Dis. 2025 Dec 9:13872877251400780. doi: 10.1177/13872877251400780.
    PubMed         Abstract available
    
    
51. ASNACIOS S, Staneva G, Thon G, Vannier F, et al
    Alzheimer's disease amyloid-beta affects membrane structure and mechanical properties of human neural progenitors.
    J Alzheimers Dis. 2025 Dec 9:13872877251398058. doi: 10.1177/13872877251398058.
    PubMed         Abstract available
    
    
52. TAKAHASHI RH, Yokotsuka M, Nakamura A, Nagao T, et al
    One of the binding proteins for administered amyloid-beta appears to be anti-Abeta IgG antibody in amyloid plaques.
    J Alzheimers Dis. 2025;108:1614-1625.
    PubMed         Abstract available
    
    
53. IMPERIALE D, Marcinno A, Atzori C, Angeloro DP, et al
    Plasma pTau217/Abeta(42) and pTau217 outperform pTau181/Abeta(42) and pTau181 in predicting cerebrospinal fluid amyloid positivity: A real-world retrospective study.
    J Alzheimers Dis. 2025;108:1961-1971.
    PubMed         Abstract available
    
    
54. LEE JJ, Xiong J, Phan TX, Reeder JE, et al
    Impaired cooperation and prosocial learning during trust game in behavioral variant frontotemporal dementia.
    J Alzheimers Dis. 2025;108:1807-1818.
    PubMed         Abstract available
    
    
55. KANDEEL M, Mahmoud M
    Comparative efficacy and safety of different brexpiprazole doses for agitation in Alzheimer's disease: A systematic review and network meta-analysis.
    J Alzheimers Dis. 2025 Dec 8:13872877251404500. doi: 10.1177/13872877251404500.
    PubMed         Abstract available
    
    
56. KIANI I, Mohseni G, Hassani T, Taghilou A, et al
    Posterior cingulate cortex atrophy across the Alzheimer's disease spectrum: A cross-sectional MRI study linking volumetrics to cognitive decline.
    J Alzheimers Dis. 2025 Dec 8:13872877251401612. doi: 10.1177/13872877251401612.
    PubMed         Abstract available
    
    
57. ZHANG S, Wang T, Xue G, Zheng R, et al
    Dysregulated mTOR signaling in Alzheimer's disease: Linking pathogenic mechanisms to emerging therapeutic strategies.
    J Alzheimers Dis. 2025 Dec 8:13872877251400667. doi: 10.1177/13872877251400667.
    PubMed         Abstract available
    
    

    
    JAMA

58. RUBIN R
    Alzheimer Disease Blood Test Cleared for Primary Care, but Questions Remain About Its Use.
    JAMA. 2025 Dec 5. doi: 10.1001/jama.2025.21573.
    PubMed        
    
    

    
    Lancet Neurol

59. MORGAN J
    Takeshi Iwatsubo: a pioneer in Alzheimer's disease research.
    Lancet Neurol. 2026;25:33.
    PubMed        
    
    

    
    Neurobiol Aging

60. KARA F, Joers JM, Przybelski SA, Algeciras-Schimnich A, et al
    (1)H-MR spectroscopy biomarkers are associated with plasma-derived biomarkers of amyloid-beta and tau in the early phase of AD continuum.
    Neurobiol Aging. 2026;158:18-27.
    PubMed         Abstract available
    
    
61. DINTICA CS, Johnson L, Petersen M, O'Bryant S, et al
    Depressive symptoms and plasma AT(N) biomarkers among cognitively healthy and mild cognitively impaired in a diverse cohort.
    Neurobiol Aging. 2026;158:11-17.
    PubMed         Abstract available
    
    
62. AUMONT E, Hall BJ, Chan T, Trudel L, et al
    Optimized atlas for early tau-PET staging via native space segmentations.
    Neurobiol Aging. 2026;158:1-10.
    PubMed         Abstract available
    
    

    
    Neurology

63. JUNG YH, Cho J, Lee SY, Seo HE, et al
    Impact of Cerebral Microbleeds on Tau-Associated Cognitive and Structural Decline.
    Neurology. 2026;106:e214453.
    PubMed         Abstract available
    
    
64. BENDER AC, Berezuk C, Pellerin KR, You JC, et al
    Association of Sleep Spindle Activity With Cognitive Decline in Early Clinical Stages of Alzheimer Disease.
    Neurology. 2026;106:e214459.
    PubMed         Abstract available
    
    
65. FERREIRA PCL, Bellaver B, Povala G, Bauer-Negrini G, et al
    Evaluating Plasma p-tau217 as an Endpoint for Alzheimer Disease Clinical Trials.
    Neurology. 2026;106:e214441.
    PubMed         Abstract available
    
    

    
    Neurosci Lett

66. WU J, Zhou L, Lang C
    Neuro-protection of swertisin against impairment induced by Abeta(25-35) by acting on COX-2 to up-regulate 2-AG and suppressing neuroinflammation.
    Neurosci Lett. 2026;870:138429.
    PubMed         Abstract available
    
    

    
    Neuroscience

67. SHENG J, Wang L, Zhang Q, Chien Chou JT, et al
    Integrating multimodal data to identify single nucleotide polymorphism-related biomarkers and regulatory mechanisms in Alzheimer's disease.
    Neuroscience. 2025 Dec 11:S0306-4522(25)01169.
    PubMed         Abstract available
    
    
68. ELKANA O, Segal O, Beheshti I
    Beyond brain scans: verbal memory testing as an efficient cognitive biomarker for preclinical Alzheimer's disease.
    Neuroscience. 2025;593:8-17.
    PubMed         Abstract available
    
    

    
    PLoS One

69. AHMED TF, Ahmed A, Haque Z, Azmi MB, et al
    Mapping the microRNA-mediated crosstalk between insulin resistance and Alzheimer's disease: A computational genomic insight.
    PLoS One. 2025;20:e0329056.
    PubMed         Abstract available
    
    
70. 
    Correction: Integration of wearable devices and artificial intelligence in Alzheimer's disease: A scoping review protocol.
    PLoS One. 2025;20:e0339031.
    PubMed         Abstract available
    
    
71. HE Y, Yan Z, Liang Y, Yu Y, et al
    Abnormal brain network reconfiguration in neuropsychiatric disorders across cognitive decline, Depression, and Schizophrenia.
    PLoS One. 2025;20:e0337470.
    PubMed         Abstract available
    
    
72. ZHOU Y, Huang Y, Fan Y, Xue F, et al
    Co-regulation of microglial subgroups in Alzheimer's amyloid pathology: Implications for diagnosis and drug development.
    PLoS One. 2025;20:e0337741.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

73. WAGH AR, Glickman MH
    Molecular mechanisms underlying p62-dependent secretion of the Alzheimer-associated ubiquitin variant UBB(+1).
    Proc Natl Acad Sci U S A. 2025;122:e2504528122.
    PubMed         Abstract available
    
    

    
    Science

74. 
    Erratum for the Report "Site-specific phosphorylation of tau inhibits amyloid-beta toxicity in Alzheimer's mice" by A. Ittner et al.
    Science. 2025;390:eaee4634.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge.